The new weight loss drug offers promising results for those who are overweight or obese. Learn about how Zepbound works, its ...

Pharm Exec’s 20th Annual Pipeline Report examines the emerging drug development trends and surging investments in five ...

For years, conventional wisdom has been that weight loss is a matter of willpower. Those who are overweight or obese just need to try harder to eat less and exercise more. But while diet and ...

In the face of abrupt weight loss, one of the most common consequences is hair loss, even after bariatric surgery. Losing ...

Researchers from the Rutgers Robert Wood Johnson Medical School and the Children's Hospital of Orange County discovered a ...

Congenital generalized lipodystrophy (CGL) is a rare autosomal recessive disorder characterized by a near-total absence of ...

For permission requests, please contact NEJM Reprints at [email protected] Select the format you want to export the citation of this publication.

In the SURMOUNT-1 trial in people with obesity or overweight with weight-related complications, 72-week tirzepatide treatment led to clinically meaningful body weight and blood pressure reduction.

From the Thorndike Memorial Laboratory, Second and Fourth Medical Services (Harvard), Boston City Hospital, the Department of Medicine, Harvard Medical School, and the Collis P. Huntington ...

Manufactured by Eli Lilly and Company, both Mounjaro and Zepbound contain the active ingredient tirzepatide. Tirzepatide is similar to semaglutide, which is used in medications like Ozempic, Rybelsus, ...

Love is in the air, and Hallmark will be one of the many networks focusing at least some of their programming around Valentine’s Day for the next month of the 2025 TV schedule. Fans of the ...